Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Companies Urge Reduced Barriers To Access Ahead Of UN Meeting On Non-communicable Disease In Developing Countries

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - The growing incidence of non-communicable diseases is driving health authorities, non-governmental organizations and pharmaceutical companies to shift priorities. In September, the United Nations plans to hold a high level meeting on NCDs to address "prevention and control," particularly in developing countries

You may also be interested in...



Ahead Of UN Meeting, Stakeholders Urged To Embrace Fight Against NCDs - IFPMA Report

HONG KONG - Large discrepancies in wealth, weak access to healthcare and poor distribution networks are among the key challenges developing nations face in tackling the growing threat of non-communicable diseases

Ahead Of UN Meeting, Stakeholders Urged To Embrace Fight Against NCDs - IFPMA Report

HONG KONG - Large discrepancies in wealth, weak access to healthcare and poor distribution networks are among the key challenges developing nations face in tackling the growing threat of non-communicable diseases

Can Milestone-based Prizes Spur Development Of Global Health Solutions?

HONG KONG - A team from BIO Ventures for Global Health (BVGH) is in Washington, DC, this week seeking support for a proposed milestone-based prize to stimulate R&D for point-of-care fever diagnostics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel